The month in numbers

Every headline metric fell except the median and the cash share. That combination is the month in one line: buyers were fewer and more selective, but those who moved committed real capital rather than optionality.

M&A took 60% of value on 31% of the deals

M&A generated $27.8 billion across 42 transactions and settled 85 cents of every announced dollar at signing. Licensing and options produced $16.1 billion across 66 deals but paid just 17 cents upfront, the balance deferred into milestones and royalties. Divestitures and carve-outs added $2.5 billion across 12 deals, commercialization $0.01 billion across 11.

The two extremes sat in the same top five. Vertex committed 100% of a $10 billion headline at signing for a commercial-stage endocrine franchise. QuantumCell licensed AlzeCure’s ACD-856 against a $2.2 billion headline with $12 million upfront, a ratio of 0.5%, which is maximum optionality at minimum commitment.

Anatomy of the five largest

Five transactions framed the month. Three were cash acquisitions carrying full premiums for assets with data behind them; two were structured bets where almost nothing was committed at signing.

The 20 largest deals of July 2026

Biopharma dominates by count, but the tail is instructive: a design-software acquisition at number six, a packaging carve-out at ten, and a bioprocessing tools deal at eleven. The largest capital in healthcare continues to move outside drugs.

A soft month inside a rising year

Monthly deal value is lumpy, and July is the third-softest month in the trailing twelve. The rolling twelve-month total nonetheless stands at $751.6 billion, still above the whole of FY2025, and the seven months to July are running 43% ahead of the same period last year. July is a dip in the series, not a break in it.

One note for readers of the H1 edition, which projected a $768 billion full year by doubling the half. The card above reports something different: $440 billion is seven months of actual value, not a full-year figure. Reaching $768 billion requires $65.6 billion a month from August, against $63.2 billion actually delivered over the last five months and $62.3 billion over the same months of 2025. On like-for-like growth the year tracks closer to $884 billion. The H1 projection stands.

The conviction line is the one to watch. Cash share ran 32% in May and 58% in June before reaching 61% in July, its second-highest reading since March’s 70%. Months that skew to M&A push the ratio to 60% and above; licensing-heavy months drop it below 35%. July was decisively the former.

The China route cooled to 11% of value

The defining structural trade of H1 contributed materially less in July. Chinese biotechs out-licensed $5.3 billion across 12 deals, roughly 11% of all July value, against approximately 24% across the first half. Greater China as a buyer accounted for three deals and $0.12 billion, an asymmetry that persists even as the volume falls.

One buyer accounts for most of it. AstraZeneca signed three of the six disclosed China-sourced deals, carrying $5.17 billion of value across four transactions in total, making it July’s most active dealmaker by count. Strip AstraZeneca out and the China route contributed under $2 billion for the month. Whether July marks genuine cooling or a single quiet month in a structural trade is the open question for August.

Oncology fell to fourth

The leaderboard inverted. Cardio-Metabolic took $14.8 billion, almost entirely on Crinetics, against $0.9 billion in July 2025. Immunology and Inflammation followed at $8.0 billion on the argenx, J&J and Innovent transactions, and Neurology reached $6.7 billion on AtaiBeckley and AlzeCure. Cancer, which carried close to 40% of H1 value, took $5.5 billion and fourth place.

Oncology at fourth is a one-month artefact of a single $10 billion endocrine deal. Oncology at 20 deals, level with Immunology and Neurology, is the real reading.

Count tells a steadier story than value. Oncology, Immunology and Neurology each ran 20 deals; Cardio-Metabolic ran 18. The ranking flipped because one transaction was worth more than the other three leaders’ largest deals combined, not because cancer dealmaking stopped.

AI held second while small molecules fell 79%

Classified against the fixed technology clusters, July’s platform activity concentrated in two places. AI and computational discovery reached $8.05 billion across 14 deals, up 268% year-over-year, holding the second-largest category on the strength of the Sail, ArisGlobal, CSPC and Insilico transactions. Small molecules fell 79% to $6.0 billion from an unusually large July 2025 base.

Two clusters deserve a flag rather than a headline. Cell and gene therapy fell 75% to $0.56 billion across seven deals, its weakest month in the record, and RNA and oligonucleotide dealmaking stayed thin at $0.36 billion. Both are volume-healthy and value-poor, which is what a sector looks like when the deals being done are early and small.

Venture thinned, the public window widened

Company financing and dealmaking moved in opposite directions. Venture raised $2.85 billion across 72 rounds, down from $4.25 billion across 77 rounds a year earlier, and mega-rounds of $100 million or more thinned from 14 to five. The public side went the other way: 12 listings raised $0.91 billion, double June’s six and July 2025’s six.

Geography is the quiet signal. The three largest rounds of the month went to companies in Sweden, the United States and Australia, and 33 of 84 financings were raised outside the US. Series C carried more capital ($1.15 billion across four rounds) than Series A and Seed combined ($0.29 billion across 30), which is the late-stage concentration that has defined the year.

AstraZeneca on breadth, Vertex on size

No single dealmaker dominated July the way Lilly dominated H1. AstraZeneca signed four transactions worth $5.17 billion, three of them China-sourced, making it the month’s most active buyer by count. Vertex signed two worth $10.03 billion, effectively all of it in one cheque.

The premium column carries the month’s real information. Three of the five largest premiums were paid for assets with human data, and the two lowest premiums in the record, both 6%, went to tools and diagnostics targets (Repligen-BioLife, Tempus-Personalis) where the buyer was consolidating capability rather than acquiring optionality.

What July is telling us

July’s signal is selectivity, not slowdown. Every volume metric fell, but the buyers who moved paid at a rate the record has not seen: a 102% premium at the top, 61% of announced value settled in cash, and three of the five largest premiums attached to assets with human data behind them. The month reads as a market that has stopped browsing.

Beneath that, two rotations deserve tracking rather than conclusions. Oncology’s fall to fourth is arithmetic, driven by a single $10 billion endocrine acquisition, and its 20-deal count is unchanged from the leaders. The China route’s drop from roughly a quarter of H1 value to 11% of July’s is the more consequential number, and it rests almost entirely on one buyer: without AstraZeneca’s three pacts the route contributed under $2 billion. One quiet month does not end a structural trade, but it is the first month of 2026 in which the trade did not lead.

The financing picture inverted the deal picture. Venture thinned to $2.85 billion with mega-rounds down from 14 to five, while twelve companies listed, double the prior month. Capital is still available to biotech, but it is increasingly available on public terms rather than private ones, which over time reduces the exit pressure that has pushed companies toward early, cheap licensing.